Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Recommendation of “Buy” from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been given a consensus rating of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $25.67.

A number of brokerages have recently commented on ATXS. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. JMP Securities began coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC lifted its position in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares during the period. New York State Common Retirement Fund increased its holdings in Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 4,300 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Astria Therapeutics in the fourth quarter valued at $107,000. PDT Partners LLC purchased a new position in Astria Therapeutics in the third quarter valued at $140,000. Finally, SG Americas Securities LLC purchased a new position in Astria Therapeutics in the third quarter valued at $155,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $7.45 on Friday. The company has a market cap of $420.43 million, a P/E ratio of -3.56 and a beta of 0.67. The firm has a 50-day simple moving average of $8.70 and a two-hundred day simple moving average of $10.34. Astria Therapeutics has a 1 year low of $7.16 and a 1 year high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.